• Vaccine Name: Recombinant baculovirus encoding HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1))
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004169
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Influenza A virus (A/Puerto Rico/8/1934(H1N1)) HA hemagglutinin
• HA gene engineering:
  • Type: DNA vaccine construction
  • Description: The baculovirus transfer vector, pAcCAG-HA, was constructed by inserting the full-length HA cDNA (kindly provided by Dr. S. Nakada, Yamanouchi Pharmaceutical, Tokyo, Japan) into the cloning site of the baculovirus transfer vector, pAcCAGMCS. The recombinant baculovirus containing the influenza virus HA genome (AcCAG-HA) was generated by homologous recombination of the transfer vector and linearized baculovirus DNAs (BD PharMingen) after cotransfection into S. frugiperda 9 cells (Abe et al., 2003).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intranasal

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: The baculoviruses (AcCAG-HA or AcNPV) (1.1 x 10^8 PFU/mouse) were inoculated twice, 2 wk apart, into the abdominal epidermis of BALB/c female mice (6-wk-old) obtained from Charles River Breeding Laboratories (Kanagawa, Japan) (Abe et al., 2003).
• Challenge Protocol: A lethal challenge with influenza virus consisting of 5.6 x 10^5 PFU of mouse-adapted A/PR/8/34 influenza virus (100 LD50) in 50 µl of saline was administered intranasally 3 wk after the second immunization (Abe et al., 2003).
• Efficacy: A recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, was constructed. Protection from a lethal challenge of the influenza virus was achieved by intranasal immunization of the recombinant baculovirus (Abe et al., 2003).